Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Nathalie Godefroid is active.

Publication


Featured researches published by Nathalie Godefroid.


Journal of The American Society of Nephrology | 2007

Transcriptional and Functional Analyses of SLC12A3 Mutations: New Clues for the Pathogenesis of Gitelman Syndrome

Eva Riveira-Munoz; Qing Chang; Nathalie Godefroid; Joost G. J. Hoenderop; René J. M. Bindels; Karin Dahan; Olivier Devuyst

Gitelman syndrome (GS) is a recessive salt-losing tubulopathy that is caused by mutations in the SLC12A3 gene that encodes the sodium-chloride co-transporter (NCC). GS is characterized by significant inter- and intrafamilial phenotype variability, with early onset and/or severe clinical manifestations in some patients. No correlations between the disease variability and the position/nature of SLC12A3 mutations have been investigated thus far. In this study, extensive mutational analyses of SLC12A3 were performed in 27 patients with GS, including genomic DNA sequencing, multiplex ligation-dependent probe amplification, cDNA analysis, and quantification of allele-specific transcripts, in parallel with functional analyses in Xenopus laevis oocytes and detailed phenotyping. Twenty-six SLC12A3 mutations were identified in 25 patients with GS, including eight novel (detection rate 80%). Transcript analysis demonstrated that splicing mutations of SLC12A3 lead to frameshifted mRNA subject to degradation by nonsense-mediated decay. Heterologous expression documented a novel class of NCC mutants with defective intrinsic transport activity. A subgroup of patients presented with early onset, growth retardation, and/or detrimental manifestations, confirming the potential severity of GS. The mutations that were associated with a severe presentation were the combination at least for one allele of a missplicing resulting in a truncated transcript that was downregulated by nonsense-mediated decay or a nonfunctional, cell surface-absent mutant. The most recurrent mutation on the second allele was a newly described NCC mutant that affected the functional properties of the co-transporter. These data suggest that the nature/position of SLC12A3 mutation, combined with male gender, is a determinant factor in the severity of GS and provide new insights in the underlying pathogenic mechanisms of the disease.


Journal of The American Society of Nephrology | 2006

Genetic Investigation of Autosomal Recessive Distal Renal Tubular Acidosis: Evidence for Early Sensorineural Hearing Loss Associated with Mutations in the ATP6V0A4 Gene

Rosa Vargas-Poussou; Pascal Houillier; Nelly Le Pottier; Laurence Strompf; Chantal Loirat; Véronique Baudouin; Marie-Alice Macher; Michèle Déchaux; Tim Ulinski; François Nobili; Philippe Eckart; Robert Novo; Mathilde Cailliez; Rémi Salomon; Hubert Nivet; Pierre Cochat; Ivan Tack; Anne Fargeot; François Bouissou; Gwenaelle Roussey Kesler; Stéphanie Lorotte; Nathalie Godefroid; Valérie Layet; Gilles Morin; Xavier Jeunemaitre; Anne Blanchard

Mutations in the ATP6V1B1 and ATP6V0A4 genes, encoding subunits B1 and 4 of apical H(+) ATPase, cause recessive forms of distal renal tubular acidosis (dRTA). ATP6V1B mutations have been associated with early sensorineural hearing loss (SNHL), whereas ATP6V0A4 mutations are classically associated with either late-onset SNHL or normal hearing. The phenotype and genotype of 39 new kindreds with recessive dRTA, 18 of whom were consanguineous, were assessed. Novel and known loss-of-function mutations were identified in 31 kindreds. Fourteen new and five recurrent mutations of the ATP6V0A4 gene were identified in 21 families. For the ATP6V1B1 gene, two new and two previously described mutations were identified in 10 families. Surprisingly, seven probands with ATP6V0A4 gene mutations developed severe early SNHL between the ages of 2 mo and 10 yr. No mutation was detected in eight families. These data extend the spectrum of disease-causing mutations and provide evidence for genetic heterogeneity in SNHL. The data also demonstrate that mutations in either of these genes may cause early deafness, and they highlight the importance of genetic screening for recessive forms of dRTA independent of hearing status.


The Journal of Clinical Endocrinology and Metabolism | 2008

GNAS defects identified by stimulatory G protein alpha-subunit signalling studies in platelets.

Kathleen Freson; Benedetta Izzi; Veerle Labarque; Monique Van Helvoirt; Chantal Thys; Christine Wittevrongel; Marie Bex; Roger Bouillon; Nathalie Godefroid; Willem Proesmans; Francis de Zegher; Jaak Jaeken; Chris Van Geet

CONTEXT GNAS is an imprinted region that gives rise to several transcripts, antisense transcripts, and noncoding RNAs, including transcription of RNA encoding the alpha-subunit of the stimulatory G protein (Gsalpha). The complexity of the GNAS cluster results in ubiquitous genomic imprints, tissue-specific Gsalpha expression, and multiple genotype-phenotype relationships. Phenotypes resulting from genetic and epigenetic abnormalities of the GNAS region include Albrights hereditary osteodystrophy, pseudohypoparathyroidism types Ia (PHPIa) and Ib (PHPIb), and pseudopseudohypoparathyroidism (PPHP). OBJECTIVE The aim was to study the complex GNAS pathology by a functional test as an alternative to the generally used but labor-intensive erythrocyte complementation assay. DESIGN AND PATIENTS We report the first platelet-based diagnostic test for Gsalpha hypofunction, supported by clinical, biochemical, and molecular data for six patients with PHPIa or PPHP and nine patients with PHPIb. The platelet test is based on the inhibition of platelet aggregation by cAMP, produced after Gsalpha stimulation. RESULTS Platelets are easily accessible, and platelet aggregation responses were found to reflect Gsalpha signaling defects in patients, in concordance with the patients phenotype and genotype. Gsalpha hypofunction in PHPIa and PPHP patients with GNAS mutations was clearly detected by this method. Mildly decreased or normal Gsalpha function was detected in patients with PHPIb with either an overall or exon 1A-only epigenetic defect, respectively. Platelet Gsalpha expression was reduced in both PHPIb patient groups, whereas XLalphas was up-regulated only in PHPIb patients with the broad epigenetic defect. CONCLUSION The platelet-based test is a novel tool for establishing the diagnosis of Gsalpha defects, which may otherwise be quite challenging.


Kidney International | 2012

Autosomal dominant polycystic kidney disease is associated with central and nephrogenic defects in osmoregulation

Thien Anh Ho; Nathalie Godefroid; Damien Gruzon; Jean-Philippe Haymann; Céline Maréchal; Xueqi Wang; Andreas L. Serra; Yves Pirson; Olivier Devuyst

Autosomal dominant polycystic kidney disease (ADPKD) is associated with a urine-concentrating defect attributed to renal cystic changes. As PKD genes are expressed in the brain, altered central release of arginine vasopressin could also play a role. In order to help determine this we measured central and nephrogenic components of osmoregulation in 10 adults and 10 children with ADPKD, all with normal renal function, and compared them to 20 age- and gender-matched controls. Overnight water deprivation caused a lower rise in urine osmolality in the patients with ADPKD than controls, reflecting an impaired release of vasopressin and a peripheral defect in the patients. The reactivity of plasma vasopressin to water deprivation, as found in controls, was blunted in the patients with the latter showing lower urine osmolality for the same range of plasma vasopressin. The maximal urine osmolality correlated negatively with total kidney volume. Defective osmoregulation was confirmed in the children with ADPKD but was unrelated to number of renal cysts or kidney size. Thus, patients with ADPKD have an early defect in osmoregulation, with a blunted release of arginine vasopressin. This reflects expression of polycystins in hypothalamic nuclei that synthesize vasopressin, and this should be considered when evaluating treatments targeting the vasopressin pathway in ADPKD.


Pediatric Transplantation | 2009

Two-step transplantation for primary hyperoxaluria: Cadaveric liver followed by living donor related kidney transplantation

Ivone Malla; Philippe A. Lysy; Nathalie Godefroid; Françoise Smets; Jaques Malaise; Raymond Reding; Etienne Sokal

Abstract:  In PH, PLTX, although ideal in theory, is rarely achieved. Patients usually have reached end‐stage kidney disease while requiring combined liver and kidney transplantation. In this combined procedure, the sudden high oxalates mobilization from blood and tissue stores jeopardizes the success of the kidney graft, with a high risk of post‐transplant early kidney necrosis or chronic graft damage. Here, we report the case of a three‐yr‐old girl with PH and ESRF in whom we performed sequentially deceased donor liver transplantation followed four months later by living donor kidney transplant, after normalization of blood oxalate levels and improvement of urinary oxalate output. After this two‐step transplantation, our patient showed normalization of renal function with good urinary output and maintained normal blood oxalate levels. This strategy seems to be a reasonable approach in order to avoid acute renal tubular injury because of oxalate excretion in these patients.


Transplantation | 2015

Corticosteroid-Free Kidney Transplantation Improves Growth: 2-Year Follow-up of the TWIST Randomized Controlled Trial.

Nicholas J. A. Webb; Sarah E. Douglas; Azita Rajai; Stephen A Roberts; Ryszard Grenda; Stephen D. Marks; Alan R. Watson; Maggie Fitzpatrick; Karel Vondrak; Heather Maxwell; Jeno Járay; Rita Van Damme-Lombaerts; David V. Milford; Nathalie Godefroid; Pierre Cochat; Milos Ognjanovic; Luisa Murer; Mignon McCulloch; Burkhard Tönshoff

Background Corticosteroid withdrawal (CW) after pediatric kidney transplantation potentially improves growth while avoiding metabolic and other adverse events. We have recently reported the results of a 196 subject randomized controlled trial comparing early CW (tacrolimus, mycophenolate mofetil (MMF), daclizumab, and corticosteroids until day 4) with tacrolimus, MMF, and corticosteroid continuation (CC). At 6 months, CW subjects showed better growth with no adverse impact on acute rejection or graft survival (Am J Transplant 2010; 10: 828–836). This 2-year investigator-driven follow-up study aimed to determine whether improved growth persisted in the longer term. Methods Data regarding growth, graft outcomes and adverse events were collected at 1 year (113 patients) and 2 years (106 patients) after transplantation. The primary endpoint, longitudinal growth calculated as delta height standard deviation score, was analyzed using a mixed model repeated measures model. Results Corticosteroid withdrawal subjects grew better at 1 year (difference in adjusted mean change, 0.25; 95% confidence interval, 0.10, 0.40; P = 0.001). At 2 years, growth remained numerically better in CW subjects (0.20 (−0.01, 0.41); P = 0.06), and significantly better in prepubertal subjects (0.50 (0.16, 0.84); P = 0.004). Bacterial and viral infection was significantly more common in CW subjects at 1 year only. Corticosteroid withdrawal and CC subjects received similar exposure to both tacrolimus and MMF at 1 and 2 years. No significant difference in patient or graft survival, rejection, estimated glomerular filtration rate, or other adverse events was detected. Conclusion Early CW effectively and safely improves growth up to 2 years after transplantation, particularly in prepubertal children.


Nephrology Dialysis Transplantation | 2012

Important differences in management policies for children with end-stage renal disease in the Netherlands and Belgium--report from the RICH-Q study.

Wilma F. Tromp; Nikki J. Schoenmaker; Johanna H. van der Lee; Brigitte Adams; Antonia H. Bouts; Laure Collard; Karlien Cransberg; Rita Van Damme-Lombaerts; Nathalie Godefroid; Koenraad van Hoeck; Linda Koster-Kamphuis; Marc R. Lilien; Ann Raes; Martin Offringa; Jaap W. Groothoff

BACKGROUND The low prevalence of childhood end-stage renal disease and the small centre sizes have been a barrier for clinical studies and the development of evidence-based guidelines for chronic renal replacement therapy (cRRT) in children. Few data exist on the quality of care for these patients and the applicability of existing guidelines. The aim of this study is to quantify variation in treatment policies and actually delivered care in nine centres that deliver cRRT for children. METHODS We surveyed treatment policies in all nine centres in the Netherlands and Belgium and compared them with the actually provided therapies and with recommendations from available guidelines. Data on treatment policies were gathered by questionnaires; actually provided care and outcomes were registered prospectively from 2007 to 2010. RESULTS Data on policies and actual patient care were obtained from all nine centres. We found relevant differences between centres in treatment policies on various topics, e.g. estimated glomerular filtration rate threshold as an indication for initiation of cRRT, preferred initial mode of cRRT, peritoneal dialysis catheter care, haemodialysis frequency and vascular access. Discrepancies were seen between stated treatment policies and actual performed therapies. For the majority of policies, no evidence-based guidelines are available. CONCLUSIONS Health care disparities exist due to large and unwanted variation in treatment policies between hospitals providing cRRT for children. Delivered care does not live up to stated policies, for which clear and internationally accepted guidelines are lacking.


Nephrology Dialysis Transplantation | 2012

Fewer pre-emptive renal transplantations and more rejections in immigrant children compared to native Dutch and Belgian children

Wilma F. Tromp; Karlien Cransberg; Johanna H. van der Lee; Antonia H. Bouts; Laure Collard; Rita Van Damme-Lombaerts; Nathalie Godefroid; Koenraad J. Van Hoeck; Linda Koster-Kamphuis; Marc R. Lilien; Ann Raes; Nadejda Ranguelov; Jaap W. Groothoff

BACKGROUND In the Netherlands and Belgium, an increasing number of children who have end-stage renal disease (ESRD) are of non-Western origin. We analysed renal transplantation practices and outcome for immigrant ESRD children as compared to native children in both countries. METHODS All Dutch and Belgian children aged <19 years who received their first renal transplantation between 1 September 2007 and 1 January 2011 were included. Therapy characteristics and outcomes were registered prospectively on a 3-monthly basis. Immigrants were defined as children of whom one or both parents had been born outside Western European countries. Multivariable Cox regression analysis was used to quantify the hazard ratio for acute rejection. RESULTS One hundred and nineteen first renal transplant recipients were included, of which 41 (34%) were immigrants. Median [range] follow-up time of transplantation was 18 [2-28] months. Compared to native children, immigrants had pre-emptive transplantations (15 versus 32%, P = 0.040) and transplantations with a kidney from a living donor less often (24 versus 59%, P < 0.001). Survival analysis in 96 children with at least 3 months of follow-up showed an increased risk for acute rejection in immigrants adjusted for donor source, duration of dialysis and number of HLA mismatches on the DR locus [hazard ratio (95% confidence interval) 2.5 (1.1-5.9)]. CONCLUSIONS Immigrant children receive fewer pre-emptive and living donor transplantations compared to native children. After transplantation, immigrant children are at higher risk for acute rejection irrespective of the mode of transplantation.


Nephrology Dialysis Transplantation | 2014

Children of non-Western origin with end-stage renal disease in the Netherlands, Belgium and a part of Germany have impaired health-related quality of life compared with Western children

Nikki J. Schoenmaker; Lotte Haverman; Wilma F. Tromp; Johanna H. van der Lee; Martin Offringa; Brigitte Adams; Antonia H. Bouts; Laure Collard; Karlien Cransberg; Maria Van Dyck; Nathalie Godefroid; Koenraad van Hoeck; Linda Koster-Kamphuis; Marc R. Lilien; Ann Raes; Christina Taylan; Martha A. Grootenhuis; Jaap W. Groothoff

BACKGROUND Many children with end-stage renal disease (ESRD) living in Western Europe are of non-Western European origin. They have unfavourable somatic outcomes compared with ESRD children of Western origin. In this study, we compared the Health-related Quality of Life (HRQoL) of both groups. METHODS All children (5-18 years) with ESRD included in the RICH-Q project (Renal Insufficiency therapy in Children-Quality assessment and improvement) or their parents were asked to complete the generic version of the Paediatric Quality-of-Life Inventory 4.0 (PedsQL). RICH-Q comprises the Netherlands, Belgium and a part of Germany. Children were considered to be of non-Western origin if they or at least one parent was born outside Western-European countries. Impaired HRQoL for children with ESRD of Western or non-Western origin was defined as a PedsQL score less than fifth percentile for healthy Dutch children of Western or non-Western origin, respectively. RESULTS Of the 259 eligible children, 230 agreed to participate. One hundred and seventy-four children responded (response rate 67%) and 55 (32%) were of non-Western origin. Overall, 31 (56%) of the ESRD children of non-Western origin, and 58 (49%) of Western origin had an impaired total HRQoL score. Total HRQoL scores of children with ESRD of Western origin and non-Western origin were comparable, but scores on emotional functioning and school functioning were lower in non-Western origin (P=0.004 and 0.01, respectively). The adjusted odds ratios (95% confidence interval) for ESRD children of non-Western origin to have impaired emotional functioning and school functioning, compared with Western origin, were 3.3(1.5-7.1) and 2.2(1.1-4.2), respectively. CONCLUSION Children with ESRD of non-Western origin in three Western countries were found to be at risk for impaired HRQoL on emotional and school functioning. These children warrant special attention.


Archives of Disease in Childhood | 2011

Lessons learned from efforts to improve the quality of care in children with end-stage renal disease in the Netherlands and Belgium

Wilma F. Tromp; Johanna H. van der Lee; Martin Offringa; Antonia H. Bouts; Laure Collard; Karlien Cransberg; Rita Van Damme-Lombaerts; Nathalie Godefroid; Koen van Hoeck; Linda Koster-Kamphuis; Marc R. Lilien; Ann Raes; Jaap W. Groothoff

Quality improvement research strives to bridge the gap between ideal and actual care.1 Many paediatric diseases are rare, and thus there is insufficient evidence to define ‘ideal care’. Low prevalences and generally small patient numbers in centres in which children with rare diseases are treated create considerable barriers for clinical studies and for the development of evidence based guidelines. As a consequence, most existing guidelines are derived from studies in adults and lack any paediatric evidence.2 Here we focus on paediatric end-stage renal disease (ESRD) as an example of a clinical field in which these challenges are encountered.

Collaboration


Dive into the Nathalie Godefroid's collaboration.

Top Co-Authors

Avatar

Ann Raes

Ghent University Hospital

View shared research outputs
Top Co-Authors

Avatar

Karin Dahan

Université catholique de Louvain

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Karlien Cransberg

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar

Maria Van Dyck

Katholieke Universiteit Leuven

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Linda Koster-Kamphuis

Radboud University Nijmegen Medical Centre

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Brigitte Adams

Université libre de Bruxelles

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge